Additionally, for nccRCC, there is limited data on the efficacy of other targeted therapies used in RCC, such as tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR), so potential effects must be extrapolated from trials of ccRCC [14–16]. The gene discussed is MTOR; the disease is renal cell carcinoma.